| Literature DB >> 35295366 |
Bukke Ravindra Naik1, Sakalecha Anil Kumar2, N Rachegowda2, L Yashas Ullas2, R B Revanth2, Nikhilendra Reddy Venkata Sai Aluru2.
Abstract
INTRODUCTION: Coronavirus disease 2019 (COVID-19) vaccines protect against severe illness. However, data on post-vaccination COVID-19 breakthrough infections are limited.Entities:
Keywords: covid-19 infection; disease severity; healthcare workers; post-vaccination; prevalence
Year: 2022 PMID: 35295366 PMCID: PMC8917791 DOI: 10.7759/cureus.22087
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Summary of CO-RADS categories used for CT scoring
CO-RADS: COVID-19 Reporting and Data System; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; COVID-19: coronavirus disease 2019; RT-PCR: reverse transcription polymerase chain reaction
| CO-RADS score | Level of suspicion | Findings |
| CO-RADS 0 | Not interpretable | Scan technically insufficient for assigning a score |
| CO-RADS 1 | Very low | Normal or noninfectious |
| CO-RADS 2 | Low | Typical for other infections but not COVID-19 |
| CO-RADS 3 | Equivocal/unsure | Features compatible with not only COVID-19 but also other diseases |
| CO-RADS 4 | High | Suspicious of COVID-19 |
| CO-RADS 5 | Very high | Typical for COVID-19 |
| CO-RADS 6 | Proven case | Positive for SARS-CoV-2 on RT-PCR |
The CT severity score index
| Percentage of involvement (single lobe) | Score |
| 0%–5% | 1 |
| 5%–25% | 2 |
| 25%–50% | 3 |
| 50%–75% | 4 |
| 75%–100% | 5 |
Calculation of CT severity score
| CT severity | Score |
| Mild | <8 |
| Moderate | 9–15 |
| Severe | >15 |
| Total score | ~25 |
Comparison of baseline parameters between the study groups (N = 2043).
*Independent sample t-test, † Chi-square test.
COPD: chronic obstructive pulmonary disease
| Parameter | Study group | P-value | |
| Vaccinated (N = 1010) | Unvaccinated (N = 1033) | ||
| Age | 43.05 ± 13.02 | 42 ± 13.15 | 0.070* |
| Gender | |||
| Male | 621 (61.49%) | 645 (62.44%) | 0.657† |
| Female | 389 (38.51%) | 388 (37.56%) | |
| Comorbidities | |||
| History of diabetes | |||
| Yes | 393 (38.91%) | 374 (36.21%) | 0.207† |
| No | 617 (61.09%) | 659 (63.79%) | |
| History of hypertension | |||
| Yes | 338 (33.47%) | 328 (31.75%) | 0.409† |
| No | 672 (66.53%) | 705 (68.25%) | |
| History of asthma/COPD | |||
| Yes | 76 (7.52%) | 75 (7.26%) | 0.819† |
| No | 934 (92.48%) | (2.74%) | |
| Cardiac disease | |||
| Yes | 98 (9.70%) | 13 (1.26%) | <0.001† |
| No | 912 (90.3%) | 1020(98.74%) | |
Comparison of clinical parameters between the study groups (N = 2043).
*No statistical test was applied due to 0 subjects in the cells, † Chi-square test.
COVID-19: coronavirus disease 2019; RT-PCR: reverse transcription polymerase chain reaction
| Parameter | Study group | P-value | |
| Vaccinated (N = 1010) | Unvaccinated (N = 1033) | ||
| RT-PCR test for COVID-19 infection | |||
| Positive | 1010 (100%) | 1,033 (100%) | * |
| CT severity score | |||
| Normal study | 514 (50.89%) | 197 (19.07%) | <0.001† |
| Mild | 382 (37.82%) | 416 (40.27%) | |
| Moderate | 111 (10.99%) | 266(25.75%) | |
| Severe | 3 (0.3%) | 154 (14.91%) | |
Summary of vaccination status (N = 1010).
| Vaccination status | Percentages |
| First dose | 382 (37.82%) |
| Second dose | 628 (62.18%) |
Comparison of CT severity score in terms of vaccination status (N = 1010).
| CT severity score | Vaccination status | Chi-square | P-value | |
| First dose completed (N = 382) | Second dose completed (N = 628) | |||
| Normal study | 140 (36.65%) | 374 (59.55%) | 158.168 | <0.001 |
| Mild | 140 (36.65%) | 242 (38.54%) | ||
| Moderate | 101 (26.44%) | 10 (1.59%) | ||
| Severe | 1 (0.26%) | 2 (0.32%) | ||